Recruiting

Impella

Sponsor:

Abiomed Inc.

Code:

NCT06964685

Conditions

AMI Cardiogenic Shock

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Impella

Study Details

Brief summary:

The observational study titled "Observational Assessment of Support with Impella Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock (OASIS-AMICS)" aims to evaluate the safety outcomes of patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) who receive Impella CP during percutaneous coronary intervention (PCI) and who are managed with Impella best practices while receiving guideline-directed standard of care. This prospective, multicenter study will enroll up to 350 hemodynamically unstable patients with cardiogenic shock of less than 12 hours duration and acute myocardial infarction (AMI) of less than 24 hours duration. Cardiogenic shock will be confirmed by tissue hypoperfusion (lactate ≥ 2.5mmol/L and/or SvO2 <55% with a normal PaO2) and systolic blood pressure <100 mmHg and/or need for vasopressor therapy (dopamine/norepinepherine or epinephrine). Patients will be assessed for various safety endpoints, including a composite safety endpoint involving major bleeding, acute limb ischemia, and acute kidney injury. Secondary endpoints will evaluate all-cause mortality, major adverse cardiovascular and cerebrovascular events (MACCE), and hospitalizations through 1-year post-Impella implant. All patients presenting with AMICS at study sites will be screened for inclusion in the study after hospital discharge (or after death, if prior to hospital discharge). IRB approved consent waiver will be used to collect data from electronic health records from; Impella placement to discharge and post-discharge at 30 days post-Impella implant, 6 months post-Impella implant, and 1 year post-Impella implant.

Conditions

AMI Cardiogenic Shock

Study ID

NCT06964685

Start date

Jul 10, 2025

Status verified date

Jul, 2026

Completion date

Oct 30, 2028

Anticipated

Primary completion date

Sep 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Acute myocardial infarction (AMI) of <36 hours duration from symptom onset to cath lab arrival, confirmed by:

  • ECG and/or biomarker evidence of ST-segment elevation myocardial infarction (STEMI), STEMI equivalents, or new or presumed new left bundle branch block or
  • ECG and/or biomarker evidence of non-ST-segment elevation myocardial infarction (NSTEMI) and angiographic evidence of one or more culprit vessels
  • Cardiogenic shock confirmed by at least two of the following:

  • Tissue hypoperfusion, manifested by an arterial or venous blood lactate level ≥2.5 mmol/L or SvO2 <55% in the presence of a PaO2 > 90mmHg
  • Systolic blood pressure <100 mmHg or need for vasoactive agents to maintain systolic blood pressure ≥100 mmHg
  • Hemodynamic criteria represented by a cardiac index of <2.2 L/min/m\^2 or a cardiac power output ≤0.6 W
  • Cardiogenic shock that develops under one of the following conditions:

  • prior to primary PCI, with <24 hours from the onset of shock to cath lab arrival, or
  • <12 hours after initiating primary PCI
  • Patient was supported with Impella CP as the initial MCS device for cardiogenic shock
  • Age ≥18 years
  • Europe only: Subject or legally designated representative (LDR) or Independent Physician has provided written informed consent for participation in the observational study

Exclusion Criteria:

  • Any contraindication listed in the Impella CP IFU if known to be present (i.e. mural thrombus in the left ventricle; presence of a mechanical aortic valve or heart constrictive device; aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm2 or less); moderate to severe aortic insufficiency (echocardiographic assessment graded as ≥ +2); severe arterial disease precluding placement of the Impella system; presence of an atrial or ventricular septal defect (including post-infarct VSD); significant right heart failure; left ventricular rupture; cardiac tamponade; combined cardiorespiratory failure).
  • Shock principally due to a cause other than LV failure, including:

  • RV infarction, hypovolemia, anaphylaxis, hemorrhage, sepsis, myocarditis, pulmonary embolism, pneumothorax, or high cardiac output shock
  • Severe arrhythmias as the primary cause of low cardiac output, including acute bradyarrhythmias, tachyarrhythmias, or advanced heart block
  • Known mechanical complications of AMI that may cause cardiogenic shock such as free wall rupture, ventricular septal defect or papillary muscle rupture with acute mitral regurgitation
  • Procedural complication of the PCI that results in coronary perforation
  • Other mechanical circulatory support already in place for present indication, including intra-aortic balloon counter-pulsation or patients with Impella CP placement prior to transfer to the cath lab at the tertiary facility
  • Acute or chronic aortic dissection
  • Prior PCI at another institution for the present infarction
  • Thrombolytic therapy for the present infarction
  • Not obeying verbal commands after preadmission or in-hospital cardiac arrest, indicative of possible anoxic brain injury NOTE:

  • Non-intubated subjects: A positive and appropriate response to commands must be repeatable on at least two (2) instances to rule out reflex response to voice
  • Intubated subjects are excluded if: They were not following verbal commands immediately prior to intubation, or They were not clearly following verbal commands after intubation within 6 hours post-PCI
  • Infective endocarditis
  • Other severe, concomitant disease with limited life expectancy <1 year (other than cardiogenic shock)
  • Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device that has not reached the timing of its primary endpoint

Study Design

Enrollment

350 participants

Anticipated

Interventions and Outcome Measures

Interventions

Impella

US commercially approved Impella CP is the device that study inclusion will be based on. Only patients with AMICS who receive Impella CP as the first Impella device after cardiogenic shock onset will be included in the study.

Primary outcome measure

  • Composite Safety [ Time Frame: All in-hospital events through discharge, an average of 15 days ]

Central Contacts and Locations

Central contacts

Sameera Dasari, PhD

978-914-8882sdasar12@its.jnj.com

Locations

Cardiology Associates Research Group (St. Bernard's Hospital)

Recruiting

Jonesboro, Arkansas, United States, 72401

St. Joseph Hospital Orange

Recruiting

Orange, California, United States, 92868

Torrance Memorial Medical Center

Recruiting

Torrance, California, United States, 90505

NCH Rooney Heart Institute

Recruiting

Naples, Florida, United States, 34102

Straub Benioff Medical Center

Recruiting

Honolulu, Hawaii, United States, 96813

Principal Investigator:

Rayji Tsutsui

OSF Saint Francis

Recruiting

Peoria, Illinois, United States, 61637

Principal Investigator:

Marco Barzallo

Brigham and Women's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Principal Investigator:

Ajar Kochar

Henry Ford Health System

Recruiting

Detroit, Michigan, United States, 48202

New Mexico Heart

Recruiting

Albuquerque, New Mexico, United States, 87102

Bethesda North Hospital

Recruiting

Cincinnati, Ohio, United States, 45242

Saint Francis Hospital

Recruiting

Tulsa, Oklahoma, United States, 74136

Providence St. Vincent Medical Center

Recruiting

Portland, Oregon, United States, 97225

Legacy Emanuel Medical Center

Recruiting

Portland, Oregon, United States, 97227

Principal Investigator:

Amish Desai

Parkwest Medical Center

Recruiting

Knoxville, Tennessee, United States, 37923

Texas Health Presbyterian Hospital Dallas

Recruiting

Dallas, Texas, United States, 75231

UTHealth Memorial Hermann

Recruiting

Houston, Texas, United States, 77030

Principal Investigator:

Sukhdeep Basra

Methodist Hospital

Recruiting

San Antonio, Texas, United States, 78229

Inova Fairfax

Recruiting

Falls Church, Virginia, United States, 22042

Principal Investigator:

Behnam Tehrani

More Information

Sponsor

Abiomed Inc.

Last update posted

Jul 6, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Abiomed Inc. on 2026-07-06.